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Abstract
The growing prevalence of antibiotic-resistant bacteria is a global health crisis that
threatens the effectiveness of antibiotics in medical treatment. Increases in the number of
antibiotic-resistant bacteria and a drop in the pharmaceutical development of novel
antibiotics have combined to form a situation that is rapidly increasing the likelihood of a
post-antibiotic era. The development of antibiotics with novel enzymatic targets is critical to
stall this growing crisis. In silico methods of molecular modeling and drug design were
utilized in the development of novel tryptamine analogs as potential antibiotics through their
inhibition of the bacterial enzyme tryptophan synthase. Following the creation of novel
tryptamine analogs, the molecules were analyzed in silico to determine their binding affinity
to human MAOB and the E. coli α-subunit, E. coli β2-dimer and the M. tuberculosis β2-dimer
of tryptophan synthase. Ten tryptamine analogs displayed significant increases in tryptophan
synthase binding affinity and show promise as potential antibiotics and antibiotic adjuvants.
Further in silico modeling determined that the binding sites of the tryptamine analogs were
similar to wild-type tryptamine in the E. coli β2-dimer, the M. tuberculosis β2-dimer and
human MAOB, while the analogs’ binding sites to the E. coli α-subunit differed. Although no
tryptamine analogs increased tryptophan synthase binding affinity while decreasing human
MAOB binding affinity, related increases in MAOB binding affinity warrants further
research into the analogs’ potentials as MAO inhibitors. Given the increases in tryptophan
synthase binding affinity and similar β2-dimer binding sites, a provisional patent was filed on
the ten identified tryptamine analogs. Moving forward, we recommend the synthesis of the
ten identified tryptamine analogs. Following synthesis, further research should be conducted
to determine the in vitro and in vivo antibiotic properties of the ten tryptamine analogs.
3

Introduction
The Arms Race – Bacterial Evolution of Antibiotic Resistance
The pseudo-competition between human development of new antibiotics and the
subsequent evolution of different antibiotic resistant bacterial strains is akin to an arms race.
As humans develop a novel antibiotic to combat antibiotic-resistant strains of bacteria, the
competition induced by this new antibiotic and subsequent bacterial evolution results in
strains of bacteria that are resistant to the new antibiotic. Those antibiotics with the adaptive
traits to counteract the mechanisms of the antibiotic outcompete the non-resistant bacteria
and subsequently produce more antibiotic-resistant bacteria.
Bacteria can attain antibiotic resistance through two general methods. First, the
bacteria may acquire a spontaneous genetic mutation through the reproduction process that
yields resistance to the antibiotic in question. Although such a random mutation is
exceedingly rare, the rapid speed of reproduction and massive number of bacterial organisms
allows for such a resistance-causing mutation to occasionally occur. Second, a bacteria
organism may acquire antibiotic resistance from other bacteria through three methods of
horizontal gene transfer. During the process of conjugation, the bacteria come into direct
contact with another and transfer genetic material directly between the two bacterial
organisms. Bacteria can also perform transformation where they uptake exogenous DNA
fragments from their surrounding medium. Finally, in the process of transduction a
bacteriophage virus acts as an intermediate for the transfer of genetic material. The
bacteriophage uptakes bacterial chromosomal DNA into the head of the virus and this genetic
material is subsequently transferred to other bacteria the virus infects. All three
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aforementioned methods of horizontal gene transfer allow for the transfer of antibioticresistance mechanisms from one bacteria to another if the shared genetic material contains a
gene that encodes for antibiotic resistance.
Once a bacterial strain acquires antibiotic resistance these bacteria maintain a
selective advantage over their non-resistant counterparts in the presence of the antibiotic in
question. When this antibiotic is introduced the non-resistant bacteria are killed off with
relative ease and the bacteria that remain are those with the antibiotic-resistant gene. Even if
only one bacterium has acquired antibiotic-resistance, that bacterium is able to rapidly
reproduce and create entire colonies of bacteria with the same antibiotic-resistant gene after
the competition from the non-resistant counterparts is eliminated. A recent study reported
that in 2012 approximately 70% of bacteria that cause human infections were resistant to at
least one of the drugs that are commonly used to fight them (Bax and Griffin, 2012).
To eliminate the bacterial colonies that developed resistance to one antibiotic, a
second antibiotic must be introduced. While this may not present a serious issue if the
bacterial colony is only resistant to a single antibiotic, it is possible, and increasingly more
prevalent, for bacteria to be resistant to multiple antibiotics. Multiple-drug resistance (MDR)
may occur both within a single family of antibiotics and across multiple antimicrobial
families. Cross-resistance occurs when a bacterial strain is resistant to multiple antibiotics in
the same family and is usually the result of a single resistance mechanism that inhibits the
function of multiple alike antibiotics. Bacterial MDR across multiple antibiotic families
usually occurs as the result of a combination of different independent mechanisms of
resistance coded for by individual genes. Although these independent mechanisms of
resistance are coded for by different genes, several of these genes are oftentimes present on a
5

single plasmid that then may be transferred to bacteria through a single act of horizontal gene
transfer. When a bacterium receives or takes up this plasmid these multiple individual
mechanisms of resistance are then able to coexist within the bacteria organism, resulting in
MDR bacterial strains that present resistance across multiple antibiotic families (Brown,
2010). The most common example of MDR bacterial strains from multiple individual
resistance-mechanisms is methicillin-resistant S. aureus (MRSA), a bacterial strain that is
resistant to almost all known antibiotic agents as the result of multiple different mechanisms
(Nue, 1992).
Overall, the bacterial development of antibiotic resistance to the antibiotic agents that
humans discover and develop is inevitable. Gene D. Wright summarizes this inevitability
when he explains:
Bacteria are ancient organisms that have adapted to virtually all environmental
challenges on the planet. They live in environments dominated by small
molecules and have evolved both specific and nonspecific mechanisms to
evade or detoxify noxious compounds including antibiotics…There are no
irresistible antibiotics. (Wright, 2012: 25)
Regardless of the antibiotic, bacterial strains will eventually develop mechanisms that infer
resistance to the drug molecule. Bacteria have found ways to survive for millions of years
and they will undoubtedly continue to survive for millions of years more. Earlier research
noted that a recent database lists more than 20,000 potential resistance genes of
approximately 400 types found in available bacterial genome sequences (Davies and Davies,
2010). Therefore, to combat this continual development of antibiotic resistance humans need
to continually develop novel antibiotics to which bacteria have yet to develop a resistance.
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Antibiotic Drug Discovery – From Penicillin to the “Golden Age”
In 1928 Dr. Alexander Fleming discovered the first antibiotic from the mold
Penicillium notatum and mass production of penicillin began in the 1940’s. In 1941 all
strains of Staphylococus aureus were susceptible to penicillin but by 1944 particular strains
of S.aureus were able to destroy penicillin (Manfredi, 2009; Neu, 1992). Less than fifty years
later researchers observed that over 95% of S. aureus strains were resistant to penicillin and
other similar antibiotics (Nue, 1992). While the development of penicillin resistance was the
first such example of a bacteria developing antibiotic resistance, it was not unexpected. In his
1945 Nobel Prize Speech Dr. Fleming noted, “It is not difficult to make microbes resistant to
penicillin in the laboratory by exposing them to concentrations not sufficient to kill them, and
the same thing has occasionally happened in the body” (Fleming, 1945: 93). Dr. Fleming
predicted that, although his discovery was one of the most significant of the 21st century, its
clinical usefulness would begin to decline as bacteria developed resistance to the drug
through evolutionary pressures.
After the widespread success of penicillin Dr. Selman Waksman and his cohorts
began screening soil microbes for potential new antibiotic agents. In 1943 Waksman and his
graduate assistant Albert Schatz discovered Streptomycin, which successfully killed many
gram-negative bacteria, most importantly Mycobacterium tuberculosis, the bacteria
responsible for tuberculosis infections (Gottfried, 2005; White, 2011). Unfortunately, the
usefulness of Streptomycin was limited by its toxic side effects, most notably ototoxicity
(White, 2011). However, the work of Dr. Waksman’s lab in identifying soil microbes as
potential sources of antibiotic agents coupled with the widespread and continued success of
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penicillin led to what is known as the “golden age of antibiotic discovery” (White, 2011;
Davies, 2006).
The widespread commercial success of penicillin, and to a lesser degree
streptomycin, soon led to a significant investment in antibiotic research from the
pharmaceutical industry. Every major pharmaceutical company instituted major screening
programs in an effort to discover their own antibiotics. The vast majority of current antibiotic
classes were discovered during this “golden era” period spanning from the late 1940’s to
1960’s (White, 2011; Silver, 2007). By 1952, antibiotics existed to treat infections from both
gram-positive and gram-negative bacteria (Gottfried, 2005). In only a ten-year period
spanning from 1950-1960 approximately half of the antibiotics commonly used today were
discovered (Davies, 2006). The impact of this period of immense antibiotic discovery simply
cannot be understated. The development of antibiotics over this golden era is credited with
playing a central role in the transition of worldwide medicine from an “age of pestilence” to
the modern “age of degenerative [chronic] diseases” (Gottfried, 2005: 10). In 1936, before
the discovery of penicillin and other antibiotics, approximately 280,000 Americans died of
bacterial infections. Less than two decades later in 1952 this number dropped to 95,000
(Gottfried, 2005). Using population estimates at the time that drop correlates to a decrease in
the bacterial infection death rate from 216/100,000 in 1936 to 59.7/100,000 in 1952
(Gottfried, 2005). Over this same 16-year period the life expectancy at birth increased an
extraordinary 10.1 years, from 58.5 years in 1936 to 68.6 years in 1952 (Gottfried, 2005).
This increase in the average life expectancy of Americans over that 16-year period is
inevitably not entirely due to the rise of antibiotics in medical treatment. However, the effect
of antibiotics was undeniably significant, especially when considering that in the 50 years
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following 1952 the life expectancy at birth only increased another 8.7 years to 77.3 years by
2002 (Gottfried, 2005).
The implementation of penicillin and other antibiotics as a foundation of medical
treatment has saved countless lives. However, recent developments in antibiotic resistance
and a collapse in the development of new antibiotics have begun to threaten the worldwide
effectiveness of antibiotic treatments. Many researchers worry that, unless things change
soon, humans may soon be faced with a post-antibiotic era. Shockingly, Dr. Fleming
predicted this crisis a 1946 New York Times article when he stated:
The public will demand [the drug]…then will begin an era…of abuses. The
microbes are educated to resist penicillin and a host of penicillin-fast
organisms is bred out which can be passed to other individuals and perhaps
from there to others until they reach someone who gets a septicemia or a
pneumonia which penicillin cannot save. In such a case the thoughtless person
playing with penicillin treatment is morally responsible for the death of the
man who formally succumbs to the infection with the penicillin-resistant
organism. I hope this evil can be averted. (Fleming, 1946; Bartlett et al., 2013)
Over 50 years ago Dr. Fleming warned against the evil of antibiotic abuse and the subsequent
rise in antibiotic resistance. However, these warnings appeared to have fallen on deaf ears as
today the public faces an undeniable global health crisis of rapidly increase antibioticresistant bacteria coupled with an untimely and potentially devastating decrease in new
antibiotic discovery and production.

The Public Health Crisis
The appearance of antibiotic-resistant bacteria is currently a major public health crisis
that demands the attention of the scientific community. A 2016 report estimated that in the
United States two million infections a year are caused by bacteria resistant to at least one
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antibiotic (O’Neill, 2016). They approximated that the treatment of these antibiotic-resistant
strains cost the US health care system 20 billion USD in excess costs (Medina and Pieper,
2016). A 2013 study found that at least 23,000 of these two million individuals die as a
direct result of their antibiotic-resistant bacterial infections and many more die from
complications induced by these bacteria (CDC, 2013). MRSA alone is responsible for almost
11,285 deaths per year in the United States (Gross, 2013). Multiple studies estimated that
worldwide 200,000 people a year die from multi-drug resistant strains of tuberculosis (TB)
alone (Gross, 2013; CDC, 2013; RAR, 2016). A national survey of infectious disease
specialists in 2011 found that 63% of the surveyed specialists had seen an untreatable
bacterial infection resistant to all available antibiotics in the past year (Hersh et al., 2012
Spellman and Gilbert, 2014). Author Ron Daniels writes that “increasing bacterial resistance
to common antibiotics may put an ‘end to modern medicine as we know it’ (Daniels, 2012:
11).
This growing state of crisis at the hands of antibiotic-resistant bacteria is the result of
an aggregation of several issues that combine to result in the overuse of antibiotics in the
medical and agricultural industries. This overuse of antibiotics allows increased opportunity
for antibiotic-resistant bacterial strains to flourish and multiply in antibiotic filled
environments where their resistance-genes grant a selective fitness advantage. The first of
these issues is the general over prescription and overuse of antibiotics in the medical field.
Over prescription and overuse of antibiotics is a worldwide issue, however it is especially
prevalent in the United States. Past research found that individuals in the US consumed an
average of 22 antibiotic pills per year (Boeckel et al., 2010). In many states the number of
prescribed courses of one antibiotic, whereas one course represents an entire antibiotic
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treatment, exceeded the population (Gross, 2013; Ventola, 2015). Therefore in these sates
individuals on average received more than one antibiotic treatment course per year.
Worldwide the overuse of antibiotics is a worsening issue, with the worldwide antibiotic
consumption increasing 36% in the ten-year period from 2000-2010 (Boeckel et al., 2010;
Morrill and LaPlante, 2015). The issue of antibiotic overuse is exacerbated by the widespread
inappropriate prescribing of antibiotic drugs. Research has found that up to 60% of the time
doctors prescribe antibiotics they do so incorrectly, whether in situations when they are not
needed or in incorrect doses (CDC, 2013; Luty et al., 2014; Lushniak, 2104). Incorrect
dosages, especially when suboptimal, are an especially dangerous phenomenon. Subtherapeutic doses of antibiotics have been found to promote antibiotic resistance by
stimulating genetic alterations in bacterial colonies through changes in gene expression,
horizontal gene transfer and mutagenesis (Viswanatahn, 2013).
While overuse and inappropriate prescription in medicine have contributed to the
antibiotic-resistance crisis, the issue is especially amplified by the extensive use of antibiotics
in the agricultural industry. Antibiotics have long been used by farmers to treat both their
crops and livestock. Antibiotic treatment increases the overall health of the stock and crops
and therefore the overall agricultural yield increases (Michael et al., 2014; Ventola, 2015). In
total 15 million kilograms of antibiotics are used yearly in the United States, 80% in the
agricultural sector (Bartlett et al., 2013’ Spellberg and Gilbert, 2014; Ventola, 2015). Recent
research has shown that overuse of antibiotics in livestock can directly harm the humans
consuming the meat of that livestock. First, antibiotic usage in the livestock kills nonresistant bacterial strains and allows the resistant bacteria to thrive given the wealth of
resources available after the non-resistant bacteria dies. Then, these antibiotic-resistant
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bacteria are transferred to the humans who consume the meat of the livestock treated with
excessive antibiotics. These antibiotic-resistant bacteria can than then cause serious
infections in humans and be transmitted to other individuals from the initial host (CDC,
2013; Ventola, 2015).

The Current State of Antibiotic Drug Development
It would seem logical that, given the immense importance of antibiotics in medicine
and the continually worsening antibiotic resistance crisis, the investment in antibiotics
research would currently be at a high point but this is simply not the case. Instead, the
discovery of new antibiotics has essentially stalled and the financial investment in antibiotic
discovery is shockingly low. Less than a decade ago researchers noted that there were
currently no antibiotics in advanced development that successfully targeted bacteria already
resistant to currently available antibiotics (Boucher et al., 2009). Two studies both note that
all but five of the top 50 pharmaceutical companies have stopped funding antibiotics research
entirely (Boucher, 2009; O’Neill, 2016). Of the largest 18 pharmaceutical companies, 15 had
abandoned the antibiotic field by 2015 (Ventola, 2015). Overall, the researchers noted a 75%
decrease in the antibiotics approved by the FDA from the period of 1983-2007 (Boucher, et
al., 2009). They estimated the number of new FDA approved antibiotics will continue to drop
as there has been a similar decrease in the number of registered early clinical trials for new
antibiotics (Boucher, et al., 2009). Two recent studies found that only 40 antibiotics were
currently in development and only 14 of those drugs were at or past phase 3 trials (Pew,
2014; Lushniak, 2014). Dr. Lynn Silver, a leading expert on the antibiotic resistance crisis,
exclaimed that we have suffered a “discovery void” of over 30 years where efforts to
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research novel antibiotic classes have largely failed, “If you look at when things were
discovered, we stopped discovering novel antibiotics in 1987” (Chemical Sciences
Roundtable, 2014: 7).
A significant cause for this precipitous drop in the discovery and success of novel
antibiotics is financially motivated. Since Fleming and Waksman discovered the earliest
antibiotics, a vast majority of antibiotic discovery has occurred due to the effort of large
pharmaceutical companies. However, over the past thirty or so years multiple factors have
combined to de-incentivize pharmaceutical research into novel antibiotic drugs. First,
traditional approaches to discover new antibiotics have been largely unsuccessful over the
past few decades and novel approaches have proved costly and time consuming (Davies,
2006; Ventola, 2015). Also, stringent FDA clinical requirements oftentimes will take over
ten years to approve a drug and therefore by the time of approval the 20-year patent for the
drug is already halfway expired (Davies, 2006). Finally, the short and limited nature of
antibiotic treatments, along with the relatively low cost of antibiotics in the market, result in
antibiotics being a low profit drug (Davies, 2006; Ventola, 2015). Newer antibiotics are
priced at a maximum of $1,000 to $3,000 per course, compared to newer chemotherapy
drugs which can cost tens of thousands of dollars per course (Ventola, 2015). Also, drugs
used to treat chronic disorders have a significantly longer course of treatment than
antibiotics. Researcher Martin L. Katz notes that “whereas one patient might require a full
year of therapy for a chronically administered drug…most antibiotic drugs are administered
for about a week, and therefore, it would take 52 patients to achieve a similar financial
return” (Katz et, 2006: 1530). Overall, a study by the London School of Economics found
that a new antibiotic has a net present value of $-50 million, compared to a net present value

13

of +$1 billion for a new musculoskeletal drug (Ventola, 2015; Bartlett et al., 2013). The cost
of research, development, production and approval often far surpasses the financial returns a
pharmaceutical company will receive once the drug hits the market. All of this combines to
form an environment where investment in antibiotic development and production is an
unwise financial decision for pharmaceutical companies.

Identifying Tryptophan Synthase as a Potential Antibiotic Target
The research in this paper was motivated by the immense need for new antibiotics
and the relative lack of antibiotic research and development in a time of dire need. Following
extensive research, the enzyme tryptophan synthase was identified as a potential antibiotic
target. Tryptophan synthase is an essential enzyme in bacteria, yeasts, molds and plants that
catalyzes the formation of L-tryptophan from indole glycerol phosphate and L-serine (Miles,
2009). Notably, although tryptophan synthase is necessary for the survival of bacteria it is not

Fig. 1. The crystal secondary structure of wild type Salmonella typhimurium tryptophan
synthase colored according to the subunits. Red = α-subunits, blue = β2 dimer (Schneider et
al., 1998).
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present in humans and other animals. Tryptophan synthase is composed of two α-subunits
and one β2-dimer that combine to form a linear αββα complex (Miles, 2009; Fatimi et al.,
2009). The α subunit first catalyzes the reversible lyase of indoleglycerol phosphate (IGP) to
an indole group (IND) and glyceraldehyde 3-phosphate (GAP) (Lane and Kirschner, 1991).
The indole then travels through a 25 Å long hydrophobic tunnel that allows for direct
substrate channeling from the α-active site to the β-active site (Fatimi et al., 2009; Barends et
al., 2008). The β2-dimer then catalyzes the irreversible synthesis of L-tryptophan from IND
and L-serine (Lane and Kirschner, 1991). The secondary structure of tryptophan synthase can
be seen in the image above (Schneider at al., 1998).
The tryptophan produced from tryptophan synthase is essential for bacterial survival.
While tryptophan is an essential amino acid that humans and other animals must consume
through their diet, enzymatic production is the primary source of tryptophan in bacteria
(Yanofsky, 2007). Tryptophan is an amino acid required for proper protein biosynthesis and
many products of tryptophan, such as indole, are biologically essential compounds for
bacteria (Yanofsky, 2007). Multiple studies have found that in E.coli the indole generated
through tryptophan metabolism is involved in both cell-to-cell communication through
quorum sensing and biofilm formation (Yanofsky, 2007; Wang et al., 2001; Ren et al., 2004;
Winzer et al., 2002). Therefore, a significant lack of tryptophan should be fatal to bacterial
cells.
Since tryptophan is biologically essential for bacteria, the inhibition of bacterial
enzymes involved in tryptophan biosynthesis have been suggested as potential drug targets
(Dias et al., 2006; Chaudhary and Roos, 2005). Notably, all organisms that synthesize
tryptophan endogenously do so by a single route and therefore inhibition of one enzyme in
15

the tryptophan biosynthesis pathway should significantly reduce intracellular tryptophan
levels in bacteria (Dias et al., 2006). Past research briefly discussed the inhibition of
tryptophan biosynthesis as a potential source for novel antibiotic enzymatic targets when
discussing the genomic similarities between bacterial and protozoan tryptophan synthase
(Chaudhary and Roos 2005). Later research specifically recommended tryptophan synthase
as the most promising enzyme of the tryptophan biosynthesis pathway for the enzymatic
target of potential antibiotics (Dias et al., 2006). These researchers noted that tryptophan
synthase is the most extensively studied of the enzymes in the tryptophan synthesis pathway
(Dias et al., 2006). In fact, earlier research observed that phosphonated inhibitors of
tryptophan synthase are already being produced for their antimicrobial and herbicidal
potential (Finn et al., 1999). Inhibitors of tryptophan synthase have already been found to be
potentially successful broad-spectrum antibiotics (Faulkner et al., 2016).
Furthermore, previous research found that indole produced through tryptophan
metabolism is directly involved in the expression of E. coli multidrug exporter genes
(Hirakawa et al., 2005). These exporter genes are a common method of bacterial antibiotic
multidrug resistance. The researchers found that in normal conditions these multidrug
exporter genes are poorly expressed, however increased intracellular indole concentrations
led to the overexpression of the exporter genes (Hirakawa et al, 2005). The amplified
expression of the drug exporter genes, upregulated by the presence of indole, conferred
multidrug resistance to E. coli colonies (Hirakawa et al., 2005). Inhibition of tryptophan
synthase and the obstruction of tryptophan biosynthesis may therefore potentially prevent the
multidrug resistance of E. coli and other bacteria with multidrug exporter genes.
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Overall, the research suggests that tryptophan synthase is a promising target for
antibiotic enzymatic inhibition. Not only may inhibition of tryptophan synthesis succeed as a
broad-spectrum antibiotic target, but it also may act as an adjuvant, decreasing the potential
for the development of resistance to other antibiotics. In fact, a recent study found that 5alkyloxytryptamines, tryptamine analogs from same base molecule as was utilized in this
study, were successful both as broad-spectrum antibiotics and antibiotic adjuvants that
potentiated the activity of current clinical antibiotics in Gram-positive and Gram-negative
bacteria species (Faulkner et al., 2016).

Tryptamine Analogs as Novel Antibiotics

Fig. 2. Molecular structure of tryptamine.
Tryptamine has long been known as an inhibitor of bacterial tryptophan synthase.
Research in the 1960’s discovered that tryptamine significantly decreased tryptophan
synthase activity; at 500 µg/ml tryptamine completely inhibited tryptophan synthase activity
in whole cells (Frendlich and Lichstein, 1961). Furthermore, these same researchers
importantly found that tryptamine not only inhibited tryptophan synthase activity but also
repressed the growth of E.coli cultures (Freundlich and Lichstein, 1961). Although these
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study results showed that tryptamine and related molecules may be successful as potential
antibiotics, little published research can be found on the topic in the preceding three decades.

Fig. 3. Molecular structure of nematophin, a tryptamine analog antibiotic isolated from the
soil microbe Xenorhabdus nematophilus (Jianxiong et al., 1997).
Over thirty years later researchers published a paper that identified Nematophin, a
novel antibiotic from the soil microbe Xenorhabdus nematophilus (Jianxiong et al., 1997).
Nematophin was identified as a tryptamine analog and was found to be a highly active
antibiotic against both wild-type and drug-resistant strains of S.aureus (Juanxiong et al.,
1997). In the same paper these researchers also identified ten other Nematophin analogs, all
of which were tryptamine analogs and displayed antibiotic properties, albeit weaker than the
original nematophin (Jianxiong et al., 1997).
Fifteen years later, different researchers published a paper that analyzed and
identified a tryptamine-related antibiotic produced from the soil bacterium Intrasporangium
N8 (Okudoh and Wallis, 2012). An earlier study by these same scholars found that the
substance produced by the Intrasporangium was an antibiotic with significant antibacterial
activity against both Gram-positive and Gram-negative bacteria (Okudoh and Wallis, 2007).
Through the method of gas chromatography-mass spectroscopy (GC-MS) these investigators
identified that one of four components in the antibiotic substance discovered in 2007 was N-
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acetyltryptamine, a tryptamine analog (Okudoh and Wallis, 2012). Importantly, the
researchers also noted that further research identified N-acetyltryptamine as the component
responsible for the observed antibiotic qualities of the substance and that “the antibiotic
produced by Intrasporangium strain N8 has the same or a similar mechanism of action to
tryptamine” (Okudoh and Wallis, 2012: 737).
A recent study continued this research into tryptamine analogs as potential antibiotic
agents (Faulkner et al., 2016). They advanced earlier research by displaying that not only
may tryptamine analogs be potentially successful broad-spectrum antibiotics, but they may
also have applications as antibiotic adjuvants. Overall, the prior research has displayed
serious potential for tryptamine analogs as successful broad-spectrum antibiotics and
antibiotic adjuvants. However, the noticeable lack of tryptamine analogs currently in the
pipeline for eventual FDA approval and production displays a need for the development of
novel tryptamine analogs with antibiotic properties. The present work focuses on the
development of novel tryptamine analogs and their potential use as novel antibiotics targeting
the inhibition of the tryptophan synthase enzyme.
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Materials and Methods
Nomenclature and Identification System of the Tryptamine Analogs

Fig. 4. Labeled molecular diagram of the base tryptamine molecule
whereas all base atoms are labeled 1-12 and multiple possible
stereochemical arrangements at a single base atom are labeled a-d.
In order to clearly label and identify the tryptamine analogs we developed a
nomenclature system of the original tryptamine molecule which labeled all of the nonhydrogen atoms with the numbers 1-12. If the base atoms had multiple possible
stereochemical orientations these different orientations were labeled a – b or a – d depending
on the number available orientations. For the illustration of this nomenclature system we
used ChemDraw Professional 16.0 to draw a diagram of the labeled atoms (PerkinElmer,
2017). The labeled molecular diagram of the base tryptamine molecule is shown in Fig. 4.
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Molecular Modeling of the Tryptamine
Analogs
For modeling and design of the
tryptamine analogs we used Visual
Molecular Dynamics (VMD), a computer
program for automated modeling and
modification of molecules (Humphrey et al.,
1996). The crystal structure data of wildtype tryptamine was used as the starting
model (Nowell et al., 2002). The VMD
Molecule Molefacture program was then
used to replace specific hydrogens on the
wild-type tryptamine molecule with one of
four functional groups: amine, hydroxyl,
methyl or carbonyl. In the first round of
design each tryptamine analog only
contained one of four functional groups
attached to a numbered base atom in a
Fig. 5. Possible stereochemical orientations
of tryptamine analogs with functional
group addition at base atom 1 (White =
hydrogen, Teal = Carbon, Red = Oxygen,
Blue = Nitrogen). (A) 1a; (B) 1b; (C) 1(2).

specific stereochemical alignment. In
situations where a single base atom had
multiple available hydrogens to remove and
replace, two of the same functional group
were attached to that same base atom. The
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possible stereochemical orientations of additions to the nitrogen at base atom 1 are seen in
Fig. 5. The stereochemical alignments of the groups attached to the nitrogen were identical

Fig. 6. Possible stereochemical orientations of tryptamine analogs with a
functional group addition at base atom 3 (White = hydrogen, Teal = Carbon,
Red = Oxygen, Blue = Nitrogen). (A) 3a; (B) 3b; (C) 3c; (D) 3d; (E) 3(2)a; (F)
3(2)b.
across the other three functional groups. When performing modification on the carbons at
base atoms 2 and 3, there were four different stereochemical orientations for additions of a
single functional group and two unique stereochemical orientations for addition of two of the
same functional group. The possible stereochemical alignments of functional groups attached
at carbon 3 are seen in Fig. 6. These stereochemical orientations are consistent across all
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other functional groups and at both of the carbons at positions two and three. Finally,
additions at the carbons along the indole ring, at locations 5 and 9-12 only occurred in a
single stereochemical orientation. A second round of tryptamine analogs with multiple
functional groups attached at multiple different numbered base atoms were created soon after
the analysis of the initial binding affinity data and followed the same identification system. In
total, seventy-two unique tryptamine analogs were created through this process.

Binding Affinity Analysis of Tryptophan Synthase Subunits-Tryptamine Analogs
Complexes
For the binding affinity analyses of the complexes between the tryptophan synthase
subunits and tryptamine analogs we used PyRx, a computer program for screening libraries
of compounds against potential drug targets (Dallakyn and Olson, 2015). Three separate
crystal structures of tryptophan synthase were utilized in this study: the structures of the αsubunit and the β2-dimer of E. coli tryptophan synthase and the β2-dimer of M.tuberculosis
(Nishio et al., 2015; Nishio et al., 2016; Kachalova et al.). For the three enzyme crystal
structures we used the PDB access codes: 1V7Y, 2DH5 and 2O2E respectively. In order to
simulate the protein-ligand complexes between the tryptophan synthase subunits and
tryptamine analogs the crystal structures of the E. coli α-subunit and the E. coli and
M.tuberculosis β2-dimers were loaded directly into the PyRx program. First, before the
protein-ligand complexes were formed, all 72 of the tryptamine analogs and wild-type
tryptamine were energetically minimized using the PyRx program. After the minimization
process was completed we used the PyRx software to simulate the formation of the proteinligand complexes between the tryptophan synthase subunits and the tryptamine analogs. For
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all three tryptophan synthase subunits the entire macromolecule was selected as a potential
binding region for the tryptamine analogs. All potential binding interactions between the
tryptophan synthase subunits and each individual tryptamine analog, including wild-type
tryptamine, were then simulated. Estimates of the nine strongest binding affinities (kcal/mol)
for each protein-ligand complex were provided by PyRx. The binding affinities were
presented as negative values and the more negative the kcal/mol value the stronger the
binding affinity between the protein-ligand complex. An increase in binding affinity of – 1
kcal/mol correlated to an approximately ten-fold increase in the binding affinity between the
protein and the ligand. Between the 72 tryptamine analogs, wild-type tryptamine and three
tryptophan synthase subunits, 219 unique protein-ligand complexes were modeled and 1,971
binding affinity measurements were taken. The strongest binding affinity for each proteinligand complex was then separated and we graphed the results using the computer program R
and the package ggplot2 (R Core Team, 2016; Wickham, 2009).

Binding Affinity Analysis of Human MAOB-Tryptamine Analogs Complexes
For the binding affinity analyses of the complexes between human MAOB and the
tryptamine analogs we used PyRx again (Dallakyn and Olson, 2015). The crystal structure of
human MAOB, PDB access code 1GOS, was used as the enzymatic model for MAOB
(Binda et al., 2001). The human MAOB crystal structure and the already energetically
minimized wild-type tryptamine and tryptamine analogs were loaded directly into PyRx.
Then, we used the PyRx software to simulate the formation of protein-ligand complexes
between the MAOB enzyme and the tryptamine molecules. Again, the entire MAOB enzyme
was selected as a potential binding region for the tryptamine analogs. Estimates of the nine
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strongest binding affinities (kcal/mol) for the MAOB-wild-type tryptamine complex and each
of the 72 MAOB-tryptamine analog complexes were provided by PyRx. The strongest
binding affinity value for each complex was then separated and we again graphed the results
using the computer program R and the package ggplot 2 (R Core Team, 2016; Wickham,
2009).

Molecular Modeling of Complexes Between Tryptophan Synthase Subunits or Human
MAOB and Identified Tryptamine Analogs Complexes
For the modeling of the protein-ligand complexes between the tryptophan synthase
subunits or human MAOB and the ten identified tryptamine analogs we used the program
PyMOL (Schrödinger). Following the binding affinity analyses the protein-ligand complexes
formed in PyRx were exported to PyMOL. Within PyMOL the location the ten tryptamine
analogs bound to the surface of the tryptophan synthase subunits or human MAOB with the
highest binding affinity was visualized and analyzed. The number of hydrogen bonds that
each tryptamine analog formed with the enzyme of question was determined. Pictures of the
binding sites and hydrogen bond formations were taken for each protein-ligand complex that
the ten identified tryptamine analogs formed. This process was then repeated with the
complexes formed by wild-type tryptamine and the tryptophan synthase subunits and human
MAOB. The binding regions and hydrogen bond formation of the tryptamine analogs were
then compared to wild-type tryptamine for each of the four enzymatic targets.
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Results
Binding Affinity Analysis of Tryptophan Synthase Subunits-Tryptamine Analogs
Complexes

Fig. 7. Comparison between the binding affinities (kcal/mol) of the tryptamine analogs and
the E. coli tryptophan synthase α-subunit to the binding affinity of wild-type tryptamine and
the same subunit. The red arrows identify the ten tryptamine analogs identified for further
research.
Line plots were generated containing the highest binding affinity value of each
tryptamine analog to the E. coli α-subunit. These values were compared to the binding
affinity of wild-type tryptamine to the E. coli α-subunit. The plot of the binding affinities of
wild-type tryptamine and the tryptamine analogs to the E. coli α-subunit is presented in Fig.
7. Almost every tryptamine analog had a higher binding affinity to the E. coli α-subunit than
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wild-type tryptamine, however ten tryptamine analogs displayed a noticeably larger increase
in binding affinity than the others.

Fig. 8. Comparison between the binding affinities (kcal/mol) of the tryptamine analogs and
the E. coli tryptophan synthase β2-dimer to the binding affinity of wild-type tryptamine and
the same subunit. The red arrows identify the ten tryptamine analogs identified for further
research.
Line plots were then produced containing the highest binding affinity value of each
tryptamine analog to the E. coli β2 dimer. The binding affinities of the tryptamine analogs
were compared to the binding affinity of wild-type tryptamine to the E. coli β2 dimer. The
plot of the binding affinities of wild-type tryptamine and the tryptamine analogs to the E. coli
β2 dimer is presented in Fig. 8. The binding affinity of wild-type tryptamine to the E. coli β2
dimer was significantly stronger than the wild-type binding affinity to the E. coli α-subunit
and therefore many of the tryptamine analogs weakened the binding affinity to the E. coli β2
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dimer. However, once again there were several tryptamine analogs that displayed an
increased binding affinity to the E. coli β2 dimer. The ten analogs identified in the past
section all exhibited a greater binding affinity to the E. coli β2 dimer than wild-type
tryptamine, although in same cases other analogs caused an even greater increase in binding
affinity.

Fig. 9. Comparison between the binding affinities (kcal/mol) of the tryptamine analogs and
the M. tuberculosis tryptophan synthase β2-dimer to the binding affinity of wild-type
tryptamine and the same subunit. The red arrows identify the ten tryptamine analogs
identified for further research.
A third line plot was created containing the highest binding affinity value of each
tryptamine analog to the M. tuberculosis β2 dimer. As before, the binding affinities of the
tryptamine analogs were compared to the binding affinity of wild-type tryptamine to the M.
tuberculosis β2 dimer. This plot of the binding affinities of wild-type tryptamine and the
tryptamine analogs to the M. tuberculosis β2 dimer is presented in Fig. 9. The clear majority
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of tryptamine analogs displayed a significantly stronger binding affinity to the M.
tuberculosis β2 dimer than wild-type tryptamine. Again, although a few other analogs
demonstrated a greater increase in their binding affinities to the M. tuberculosis β2 dimer, the
ten analogs identified earlier showed a significant increase in binding affinities to the M.
tuberculosis β2 dimer.

Fig. 10. Summation of the relative differences between the binding affinities (kcal/mol) of the
tryptamine analogs and wild-type tryptamine to the three tryptophan synthase subunits used in
this paper. The red arrows identify the ten tryptamine analogs identified for further research.
To quantify the potential of the tryptamine analogs as broad-spectrum antibiotic
agents we calculated each analog’s relative change from wild-type tryptamine in binding
affinity to each of the three tryptophan synthase subunits. These three values were then added
together to ascertain each tryptamine analogs’ combined increase in relative binding affinity
to the tryptophan synthase subunits. The plot of each analog’s combined relative change from
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wild-type tryptamine in binding affinity to the three bacterial tryptophan synthase subunits is
presented in Fig.10. Several tryptamine analogs displayed a decrease from wild-type
tryptamine in the combined binding affinity to the three tryptophan synthase subunits.
However, a definite majority demonstrated an increase in the combined binding affinity to
the tryptophan synthase subunits when compared to wild-type tryptamine. Noticeably, the ten
tryptamine analogs identified in the earlier sections displayed the largest increases in the
combined relative binding affinity.
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Binding Affinity Analysis of Human MAOB-Tryptamine Analogs Complexes

Fig. 11. Comparison between the binding affinities (kcal/mol) of the tryptamine analogs and
human MAOB to the binding affinity of wild-type tryptamine to MAOB. The red arrows
identify the ten tryptamine analogs identified for further research.
After testing the effect of the tryptamine modifications on the molecules’ binding
affinities to bacterial tryptophan synthase, we utilized similar methods to test the effects of
the same modifications on the tryptamine analogs’ binding affinity to human MAOB. Line
plots were produced containing the highest binding affinity value of each tryptamine analog
to the human MAOB. Then, we compared the binding affinities of the tryptamine analogs to
human MAOB and the binding affinity of wild-type tryptamine to human MAOB. The plot
of the binding affinities of wild-type tryptamine and the tryptamine analogs to human MAOB
is presented in Fig. 11. In an attempt to visualize the differences in binding affinities to
human MAOB between the tryptamine analogs and wild-type tryptamine we created a graph
of each analog’s relative difference from wild-type tryptamine in MAOB binding affinity,
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seen in Fig.12. Although a few tryptamine analogs were able to decrease the binding affinity
to human MAOB, a significant majority displayed an increased MAOB binding affinity
when compared to wild-type tryptamine. Similarly, all ten of the promising tryptamine
analogs showed an increased human MAOB binding affinity. However, the one tryptamine
analog that involved the addition of an amine group, and not a hydroxyl group, displayed the
smallest MAOB binding affinity increase of the ten identified molecules.

Fig. 12. The relative difference in the binding affinity (kcal/mol) to MAOB of the
tryptamine analogs from wild-type tryptamine. The red arrows identify the ten tryptamine
analogs identified for further research.
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Integrating the Tryptamine Analogs’ Binding Affinities to Tryptophan Synthase and
MAOB
Finally, we designed an analysis to integrate both the tryptamine analogs’ binding
affinities to the three tryptophan synthase subunits and the analogs’ binding affinities to the
human MAOB. To accomplish this, we subtracted the relative difference in binding affinity
to MAOB between the tryptamine analogs and wild-type tryptamine from the summated
relative difference in binding affinity to the tryptophan synthase subunits between the
tryptamine analogs and wild-type tryptamine. The plot of this difference in relative binding
affinities is presented in Fig. 14. Overall, a majority of tryptamine analogs had a positive
difference in the relative binding affinity change from wild-type between the tryptophan
synthase subunits and human MAOB. Significantly, the ten aforementioned tryptamine
analogs displayed the highest differences in relative binding affinity.

Fig. 13. The difference between the combined increase in relative binding affinity
(kcal/mol) of the tryptamine analogs from wild-type tryptamine to the three tryptophan
synthase subunits and the relative difference in the binding affinity of the tryptamine
analogs from wild-type tryptamine to human MAOB. The red arrows identify the ten
tryptamine analogs identified for further research.
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Identification of the Tryptamine Analogs Deserving Synthesis and Further Research
Following the extensive binding affinity analyses, we identified ten tryptamine
analogs that present the most promise as tryptophan synthase inhibitors. The molecular
structure of these ten tryptamine analogs are pictured in Fig. 14. Nine of the most promising
tryptamine analogs included additions of one, or multiple, hydroxyl functional groups and the
tenth resulted from an addition of two amine groups at the carbon at position two. Of the nine
identified tryptamine analogs involving the addition of a hydroxyl group, one had only a
single hydroxyl group addition while the other eight resulted from the addition of multiple
hydroxyl groups at one, or several different, base atoms.
Several of the tryptamine analogs generated by the VMD program possess a
significantly stronger binding affinity than wild-type tryptamine to each of the three
tryptophan synthase subunits. Furthermore, when compared with wild-type tryptamine, the
ten most promising tryptamine analogs display an increase of 1.8 kcal/mol – 3.9 kcal/mol in
combined relative binding affinity across the three tryptophan synthase subunits. The
increases in tryptophan synthase subunit binding affinities for 1(2)+(2)b+10+11+12 hydroxyl
tryptamine molecule, the analog that exhibited the largest combined increase in relative
binding affinity, correlated to an approximately 14 times increase in the binding affinity to E.
coli tryptophan synthase α-subunit, a 9 times increase to the E. coli β2-dimer and a 16 times
increase to the M. tuberculosis β2-dimer.
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Fig. 14. Molecular structures of the ten most promising
tryptamine analogs identified through binding affinity
analyses. (A) 1(2) hydroxyl; (B) 2b hydroxyl; (C) 2(2)b
hydroxyl; (D) 2(2)b amine; (E) 3(2)b hydroxyl;
(F)
1(2)+(2)b hydroxyl; (G) 1(2)+(2)b+11 hydroxyl;
(H) 1(2)+(2)b+11+12 hydroxyl; (I) 1(2)+(2)b+10+11+12
hydroxyl; (J) 1(2)+(2)b+9+10+11+12 hydroxyl.
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Molecular Modeling of Complexes Between Tryptophan Synthase Subunits or Human
MAOB and Identified Tryptamine Analogs Complexes

Fig. 15. Molecular models of the strongest binding interactions of the E.coli tryptophan
synthase α-subunit (purple) and (WT) wild-type tryptamine, (A) 1(2) hydroxyl, (B) 2b
hydroxyl, (C) 2(2)b hydroxyl, (D) 2(2)b amine, (E) 3(2)b hydroxyl, (F) 1(2)+(2)b
hydroxyl, (G) 1(2)+(2)b+11 hydroxyl, (H) 1(2)+(2)b+11+12 hydroxyl, (I)
1(2)+(2)b+10+11+12 hydroxyl and (J) 1(2)+(2)b+9+10+11+12 hydroxyl. Yellow
numbers represent the number of hydrogen bonds in the binding interaction.
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After ten tryptamine analogs were identified through the binding affinity analyses we
modeled the strongest binding interaction of these ten tryptamine analogs to the E. coli
tryptophan synthase α-subunit. Within this model we visualized the number of hydrogen
bonds that each tryptamine analog formed with the α-subunit. The pictures of the strongest
binding interaction for the ten identified tryptamine analogs, including the hydrogen bonds
formed, is presented in Fig. 15. None of the ten identified tryptamine analogs bound with the
highest affinity to the same region of the α-subunit as wild-type tryptamine. Furthemore,
there was large variance in the the area of strongest binding affinity between the tryptamine
analogs. In total we observed five general regions of the α-subunit where one or more of the
tryptamine analogs bound with the highest affinity. However, when compared with wild-type
tryptamine, a majority of the tryptamine analogs increased the number of hydrogen bonds
formed with the α-subunit. Only one analog decreased the number of hydrogen bonds formed
with the α-subunit.
We then modeled the strongest binding interaction of the ten identified tryptamine
analogs to the E.coli tryptophan synthase β2-dimer. Within this model we visualized the
number of hydrogen bonds that each tryptamine analog formed with the β2-dimer. The
pictures of the tryptamine analogs’ strongest binding interactions with the E. coli β2-dimer,
including the hydrogen bonds formed, is presented in Fig. 16. While there was some
variation in the orientation of binding, all ten of the identified tryptamine analogs bound with
the highest affinity to the same region of the β2-dimer as wild-type tryptamine. Also, a
majority of the tryptamine analogs increased the number of hydrogen bonds formed with the
E. coli β2-dimer. No analogs decreased the number of hydrogen bonds formed with the αsubunit.
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Fig. 16. Molecular models of the strongest binding interactions of the E.coli tryptophan
synthase β2-dimer (blue) and (WT) wild-type tryptamine, (A) 1(2) hydroxyl, (B) 2b
hydroxyl, (C) 2(2)b hydroxyl, (D) 2(2)b amine, (E) 3(2)b hydroxyl, (F) 1(2)+(2)b hydroxyl,
(G) 1(2)+(2)b+11 hydroxyl, (H) 1(2)+(2)b+11+12 hydroxyl, (I) 1(2)+(2)b+10+11+12
hydroxyl and (J) 1(2)+(2)b+9+10+11+12 hydroxyl. Yellow numbers represent the number
of hydrogen bonds in the binding interaction.
Following the modeling of both E. coli tryptophan synthase subunits we modeled the
strongest binding interaction of the ten identified tryptamine analogs to the M. tuberculosis
tryptophan synthase β2-dimer. We also vizualized the number of hydrogen bonds that each
tryptamine analog formed with the β2-dimer. The pictures of the tryptamine analogs’
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Fig. 17. Molecular models of the strongest binding interactions of the M. tuberculosis
tryptophan synthase β2-dimer (green) and (WT) wild-type tryptamine, (A) 1(2) hydroxyl,
(B) 2b hydroxyl, (C) 2(2)b hydroxyl, (D) 2(2)b amine, (E) 3(2)b hydroxyl, (F) 1(2)+(2)b
hydroxyl, (G) 1(2)+(2)b+11 hydroxyl, (H) 1(2)+(2)b+11+12 hydroxyl, (I)
1(2)+(2)b+10+11+12 hydroxyl and (J) 1(2)+(2)b+9+10+11+12 hydroxyl. Yellow
numbers represent the number of hydrogen bonds in the binding interaction.
strongest binding interactions with the M. tuberculosis β2-dimer, including the hydrogen
bonds formed, is presented in Fig. 17. Again, while there were slight discrepancies in the
orientation of binding, all ten of the identified tryptamine analogs bound with the highest
affinity to the same region of the M. tuberculosis β2-dimer as wild-type tryptamine. Also,
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nearly all of the tryptamine analogs increased the number of hydrogen bonds formed with the
M. tuberculosis β2-dimer. Again, no analogs decreased the number of hydrogen bonds
formed with the β2-dimer.

Fig. 18. Molecular models of the strongest binding intereactions of the human
MAOB (red) and (WT) wild-type tryptamine, (A) 1(2) hydroxyl, (B) 2b hydroxyl,
(C) 2(2)b hydroxyl, (D) 2(2)b amine, (E) 3(2)b hydroxyl, (F) 1(2)+(2)b hydroxyl,
(G) 1(2)+(2)b+11 hydroxyl, (H) 1(2)+(2)b+11+12 hydroxyl, (I)
1(2)+(2)b+10+11+12 hydroxyl and (J) 1(2)+(2)b+9+10+11+12 hydroxyl. Yellow
numbers represent the number of hydrogen bonds in the binding interaction.
Finally, we modeled the strongest binding interaction of the ten identified tryptamine
analogs to human MAOB. We also vizualized the number of hydrogen bonds that each
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tryptamine analog formed with MAOB. The pictures of the tryptamine analogs’ strongest
binding interactions with the human MAOB, including the hydrogen bonds formed, is
presented in Fig. 18. Again, while were slight differences in the orientation of binding, all ten
of the identified tryptamine analogs bound with the highest affinity to the same region of
human MAOB as wild-type tryptamine. Exactly half of the tryptamine analogs increased the
number of hydrogen bonds formed with human MAOB. Two of the analogs decreased the
number of hydrogen bonds formed with human MAOB.
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Discussion
In silico molecular modeling enabled us to model novel tryptamine analogs and
analyze the effects of various functional group additions on the molecules’ binding affinities
to the following tryptophan synthase subunits: E. coli α-subunit, E. coli β2-dimer and the M.
tuberculosis β2-dimer. This same molecular modeling process allowed us to determine the
effects of these same functional group additions on the molecules’ binding affinities to
human MAOB. Furthermore, we were able to analyze the location on the enzymes where the
ten identified tryptamine analogs bind with the highest affinity. Our research found that
additions of certain functional groups to wild-type tryptamine can significantly increase the
molecules’ tryptophan synthase binding affinities. However, despite the successes in
increasing the tryptophan synthase binding affinity in the tryptamine analogs, we could not
model any tryptamine-like molecules that both increased tryptophan synthase binding affinity
while also decreasing the human MAOB binding affinity. Instead, the ability of the
tryptamine analogs to bind to tryptophan synthase was correlated with their ability to bind to
human MAOB. This may suggest that tryptophan synthase and human MAOB have similar
tryptamine binding sites.
From the molecular modeling of binding regions, we found that the ten tryptamine
analogs bind with the highest affinity to the same region as wild-type tryptamine in the E.
coli tryptophan synthase β2-dimer, the M. tuberculosis β2-dimer and human MAOB.
However, to the E. coli tryptophan synthase α-subunit the ten tryptamine analogs bind with
the highest affinity to a different region than wild-type tryptamine and there is variance in αsubunit binding regions across the tryptamine analogs. Compared to wild-type tryptamie, the
majority of the tryptamine analogs display an increase in the number of hydrogen bonds they
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form when bound to the three tryptophan synthase subunits, while only a small number
decrease the number of hydrogen bonds in the binding interactions. In the E. coli α-subunit
one analog increases the number of hydrogen bonds 3.5x compared to wild-type tryptamine,
in the E. coli β2-dimer the highest hydrogen bond increase is 4x, and in the M. tuberculosis
β2-dimer the greatest hydrogen bond increase is 8x. Similar to the binding affinity assays,
half of the tryptamine analogs also display an increase in the number of hydrogen bonds they
form with human MAOB when compared to wild-type tryptamine. The other half of the
analogs either exhibited the same or a decreased number of hydrogen bonds to human
MAOB.
Regardless of the increase in human MAOB binding affinity and an increase in
hydrogen bonding to MAOB in half of the analogs, the identified tryptamine analogs show
promise as tryptophan synthase inhibitors and subsequently, as novel broad-spectrum
antibiotics. Earlier studies have shown that tryptamine and tryptamine-like analogs are
potentially successful antibiotics through their inhibition of bacterial tryptophan synthase
(Freundlich and Lichestein, 1961; Jianxiong et al., 1997; Okudoh and Wallish, 2012;
Faulkner et al., 2016). Our research supports and augments this earlier research by showing
that additions of certain functional groups can significantly increase the tryptophan synthase
binding affinity, and therefore the molecules’ potential as tryptophan synthase inhibitors.
Specifically, our data identifies ten potential tryptamine analogs that provide a significant
increase from wild-type tryptamine in the bacterial tryptophan synthase binding affinity.
Multiple studies have noted that tryptamine has a high turnover rate in mammalian
brains because of MAO-catalyzed oxidative deamination (Yu, 1985; Sullivan et al., 1986).
Therefore, the correlated increase in human MAOB binding affinity alongside the increases
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in tryptophan synthase binding affinity may affect the potential effectiveness of tryptamine
analogs as clinical antibiotic agents. However, further research is required before the effects
of MAO on a tryptamine analog antibiotics can be determined. Although the strong MAOB
binding affinity of the tryptamine analogs may harm their antibiotic effects, it may introduce
another potential pharmaceutical capability. Research has found that certain tryptamine
analogs are successful MAO inhibitors in vivo (Balsa et al., 1990; Avila et al., 1993).
Therefore, given their significant increase in human MAOB binding affinity, the tryptamine
analogs identified in this paper display potential as MAO inhibitors. MAO inhibitors are
important drugs, utilized in the treatment of Parkinson’s disease and other neurological
disorders. Moving forward, future research should be dedicated to determining the
effectiveness of the tryptamine analogs as MAO inhibitors in vivo.
While the tryptamine analogs’ potential use as MAO inhibitors is both interesting and
intriguing, the primary findings of our paper consists of the identification of ten tryptamine
analogs with significant prospects as tryptophan synthase inhibitors and therefore as broadspectrum antibiotic agents. When compared to wild-type tryptamine, the ten tryptamine
analogs exhibited an approximately 18 to 39 times increase in the combined relative binding
affinity across the three tryptophan synthase subunits tested in this study. Furthermore,
although there was a correlation between increases in both the tryptophan synthase and
MAOB binding affinities, this was not a 1:1 relationship. Instead, our identified tryptamine
analogs displayed a much greater increase in tryptophan synthase subunit binding affinity
than in MAOB binding affinity. The analogs’ increases in hydrogen bond formation to the
tryptophan synthase subunits when compared to wild-type tryptamine also supports the
quantitative increases in binding affinity because increasing hydrogen bonding interactions
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should increase the binding affinity of the protein-ligand complex. This data indicates
significant potential for in vivo tryptophan synthase inhibition. Significantly increased
binding affinities to the tryptophan synthase subunits may correlate to increased inhibition of
the tryptophan synthase enzyme and subsequently increased antibiotic capabilities.
Additionally, the similarities in binding sites to the E. coli and M. tuberculosis β2dimers between wild-type tryptamine and the tryptamine analogs provide further evidence
towards the analogs’ potential as tryptophan synthase inhibitors and antibiotic agents. The
similarities in binding region suggest that the tryptamine analogs will have a similar
inhibitory effect on tryptophan synthase as wild-type tryptamine. However, the analogs did
bind to different regions on the E. coli α-subunit than wild-type tryptamine. While these
differences in binding sites may affect the functionality of the tryptamine analogs, this cannot
be guaranteed until the analogs are synthesized and tested further.
Following this research, we filed a provisional patent on the novel structures of the
ten identified tryptamine analogs. If these tryptamine analogs are successful as tryptophan
synthase inhibitors, as the in silico data suggests, they may succeed as antibiotic agents.
Consequently, these novel molecules may provide new antibiotic drugs to combat the
growing global health crisis of antibiotic resistance and help fill the discovery void of the
past three decades. Furthermore, given past research that identified tryptophan synthase
inhibitors as potential antibiotic adjuvants, these tryptamine molecules may also facilitate the
success of other clinical antibiotics (Hirakawa et al., 2004). Therefore, we propose that the
ten tryptamine analogs presented in Fig. 14 are deserving of synthesis and further in vitro and
in vivo research into their antibiotic properties.
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